ResApp Announces Massachusetts General Hospital
as First US Clinical Study Site
Perth, Western Australia, 20 July 2016 -- ResApp Health Limited (ASX: RAP), the
developer of smartphone medical applications for the diagnosis and
management of respiratory disease, today announced that it is planning to
conduct a clinical study with the Massachusetts General Hospital (MGH) for the
ResAppDx US paediatric study. The MGH is a 1,000-bed academic medical centre
located in Boston, Massachusetts. Each year, the MGH admits more than 50,000
patients, delivers nearly 4,000 babies and records 1.5 million outpatient visits,
including more than 100,000 Emergency Department visits. In 2015, the MGH
topped the Nature Index list of health care organizations for most publications in
leading scientific journals. The MGH also has always been among the top few
hospitals each year on the U.S. News & World Report list of “America's Best
Hospitals.”
“We are very pleased to be working with MGH, one of the most prestigious
hospitals in the US,” said Tony Keating, Managing Director and CEO of ResApp.
“Working with MGH will allow us to enrol large numbers of patients quickly and
provide the highest quality clinical results for our FDA de novo submission.”
Data from the study will again be analysed by The University of Queensland
team led by Associate Professor Udantha Abeyratne.
Expand
(20min delay)